ERBB2 and breast cancer: Logistic regression analysis revealed that younger age (under 50 years) (OR 2.57, 95% CI 1.04–6.88), lymph node-positive breast cancer (OR 2.10, 95% CI 1.03–4.39) and breast cancer of the HER2 positive subtype (OR 5.24, 95% CI 1.40–25.90) were correlated with higher odds of detecting a recurrence outside of planned surveillance.